Retatrutide availability is primarily through research chemical suppliers, and the market is growing as more researchers begin exploring this triple-agonist peptide
Low libido and erectile dysfunction (ED) are often linked to underlying issues like hormone imbalances, but they can also be influenced by factors such as circulation, stress, sleep, and overall cardiovascular health
Studies in patients with type 2 diabetes and obesity have demonstrated that the use of SGLT2 inhibitors, particularly empagliflozin, not only increases overall cancer risk but also significantly elevates the risk of bladder cancer [10, 108]
Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has received MHRA marketing authorisation
These medications can be incredibly helpful, but theyre not risk-free, especially during pregnancy. The study found that 2.2% of women became pregnant within six months of starting GLP-1 treatment with pregnancy rates highest among younger women with diabetes, and among women without diabetes in their early thirties
Metabolic Effects Beyond Weight Loss Both medication types improve metabolic markers, but dual agonists might offer some advantages in certain areas
